Barclays PLC Boosts Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Barclays PLC grew its holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL) by 70.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 155,179 shares of the biotechnology company’s stock after buying an additional 64,101 shares during the quarter. Barclays PLC owned 0.18% of Anavex Life Sciences worth $882,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AVXL. Bank of New York Mellon Corp increased its position in shares of Anavex Life Sciences by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock valued at $1,184,000 after buying an additional 40,895 shares in the last quarter. Rhumbline Advisers increased its position in shares of Anavex Life Sciences by 15.8% in the second quarter. Rhumbline Advisers now owns 119,289 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 16,293 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock worth $1,968,000 after acquiring an additional 386,537 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Anavex Life Sciences in the second quarter worth approximately $166,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Anavex Life Sciences in the second quarter worth approximately $191,000. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

AVXL has been the topic of a number of research analyst reports. HC Wainwright lifted their price target on Anavex Life Sciences from $40.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, December 26th. D. Boral Capital reaffirmed a “buy” rating and issued a $46.00 price target on shares of Anavex Life Sciences in a research note on Monday, December 23rd.

Anavex Life Sciences Price Performance

Shares of NASDAQ:AVXL opened at $11.04 on Tuesday. The business’s 50 day moving average price is $8.29 and its 200-day moving average price is $6.46. The firm has a market capitalization of $936.37 million, a PE ratio of -22.08 and a beta of 0.73. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. As a group, analysts expect that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.